title: Clinical Efficacy and Safety of Ixekizumab for Treatment of Psoriasis.
abstract: Psoriasis is a common, chronic, inflammatory skin disorder with a physical and emotional burden. Emerging evidence suggests that IL17-A is a key cytokine in the immunopathogenesis of psoriasis. Ixekizumab is a humanized IgG4 monoclonal antibody that acts by neutralizing IL-17A. Data from Phase I-III studies reveal that ixekizumab is highly effective in treating patients with moderate-to-severe plaque psoriasis. A large proportion of patients receiving ixekizumab achieved or maintained complete or near complete resolution of psoriatic lesions with an acceptable safety profile through week 60. These remarkable results introduce a paradigm shift in the medically management of psoriasis, where complete or almost completely clear skin becomes the new therapeutic goal.
authors.affiliation: Department of Dermatology, Centro Hospitalar do Porto, Portugal.
authors.forename: A
authors.initials: A
authors.lastname: Azevedo
authors.affiliation: Department of Dermatology, Centro Hospitalar do Porto, Portugal; Instituto de Ciências Biomédicas Abel Salazar, University of Porto, Portugal. Electronic address: torres.tiago@outlook.com.
authors.forename: T
authors.initials: T
authors.lastname: Torres
mesh_terms: D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects / Q000276:immunology / Q000627:therapeutic use*; D057134:Antibodies, Neutralizing / Q000009:adverse effects / Q000276:immunology / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000009:adverse effects / Q000276:immunology / Q000627:therapeutic use*; D002178:Candidiasis, Chronic Mucocutaneous / Q000209:etiology; D002986:Clinical Trials as Topic; D004198:Disease Susceptibility; D004311:Double-Blind Method; D000068800:Etanercept / Q000009:adverse effects / Q000627:therapeutic use; D006261:Headache / Q000209:etiology; D006801:Humans; D020381:Interleukin-17 / Q000037:antagonists & inhibitors* / Q000276:immunology / Q000502:physiology; D011565:Psoriasis / Q000188:drug therapy* / Q000276:immunology; D016032:Randomized Controlled Trials as Topic; D012141:Respiratory Tract Infections / Q000209:etiology; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D057134:Antibodies, Neutralizing; D018501:Antirheumatic Agents; C508717:IL17A protein, human; D020381:Interleukin-17; C549079:ixekizumab; C555450:secukinumab; D000068800:Etanercept
keywords: Agentes anti IL-17; Anti-IL-17 agents; Interleucina-17; Interleukin-17; Ixekizumab; Psoriasis